A BioSpace analysis of all 80 priority review vouchers that have been handed out across the three FDA programs that offer ...

For Zevra Therapeutics, last year’s approval of the rare lysosomal storage disorder drug Miplyffa appears to be the gift that ...

Zevra has sold its US Food and Drug Administration (FDA) priority review voucher (PRV) for $150m to an undisclosed party. The ...

Every investor in Porvair plc (LON:PRV) should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are institutions with 59% ownership. In other ...

Zevra Therapeutics (ZVRA) has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher ...

LaDuane Clifton, Zevra’s Chief Financial Officer said, “This non-dilutive capital strengthens our balance sheet by adding gross cash proceeds of $150 million, supporting continued investment in our ...

U.S. Energy's Volt Vault product line offers a variety of charging solutions with Level 2, Level 3, and combination units ...

Rare disease-focused biopharma Zevra Therapeutics has agreed to sell its Rare Pediatric Disease Priority Review Voucher (PRV) to an undisclosed buyer for $150 million.

1. San Antonio Brennan (28-2), Prv: 1; 2. Allen (29-1), Prv: 2; 3. Mansfield Lake Ridge (31-2), Prv: 3; 4. Alvin Shadow Creek (28-2), Prv: 4; 5. Lancaster (25-5), Prv ...

Appleton, Wis., March 03, 2025 (GLOBE NEWSWIRE) -- U.S. Energy®, a leading provider of refined products, alternative fuels, and environmental credits, delivered, set ...

1. San Antonio Brennan (26-2), Prv: 1; 2. Allen (27-1), Prv: 2; 3. Mansfield Lake Ridge (29-2), Prv: 3; 4. Alvin Shadow Creek (26-2), Prv: 5; 5. Lancaster (23-5), Prv ...